↓ Skip to main content

A double-blinded randomized controlled trial of silymarin for the prevention of antituberculosis drug-induced liver injury

Overview of attention for article published in BMC Complementary and Alternative Medicine, September 2015
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (80th percentile)
  • High Attention Score compared to outputs of the same age and source (84th percentile)

Mentioned by

twitter
8 tweeters
facebook
4 Facebook pages

Citations

dimensions_citation
21 Dimensions

Readers on

mendeley
26 Mendeley
Title
A double-blinded randomized controlled trial of silymarin for the prevention of antituberculosis drug-induced liver injury
Published in
BMC Complementary and Alternative Medicine, September 2015
DOI 10.1186/s12906-015-0861-7
Pubmed ID
Authors

Chote Luangchosiri, Ammarin Thakkinstian, Sermsiri Chitphuk, Wasana Stitchantrakul, Supanna Petraksa, Abhasnee Sobhonslidsuk

Abstract

Hepatitis is a common adverse effect of antituberculosis drugs. Silymarin prevented drug-induced hepatoxicity in animals with anti-oxidative mechanisms but its effect in human has been unknown. We aimed to evaluate the efficacy of silymarin for preventing antituberculosis-drug induced liver injury (antiTB-DILI) in patients with tuberculosis. A double-blind randomized placebo-controlled trial was performed. Tuberculosis patients were randomly allocated to receive placebo or silymarin. The outcomes of interests were antiTB-DILI and the maximum liver enzymes at week 4. Antioxidative enzymes (i.e., superoxide dismutase (SOD), glutathione and malondialdehyde assays) were assessed. The risks of antiTB-DILI between the two groups were compared. A number need to treat was estimated. A total of 55 out of 70 expected numbers of patients were enrolled. There were 1/27 (3.7 %) and 9/28 (32.1 %) patients who developed antiTB-DILI in the silymarin and the placebo groups. Risk reduction was 0.28 (0.10, 0.47), i.e., receiving silymarin was 28 % at lower risk for antiTB-DILI than placebo. This led to prevention of 28 patients from being antiTB-DILI among 100 treated patients. Median (IQR) of ALT levels at week 4 in the placebo and the silymarin group were 35.0 (15, 415) IU/L and 31.5 (20, 184) IU/L (p = 0.455). The decline of SOD level at week 4 in the silymarin group was less than the placebo group (p < 0.027). Silymarin reduced the incidence of antiTB-DILI. The benefit of silymarin may be explained from superoxide dismutase restoration. Larger clinical trials are required to confirm the result of our small study [Clinicaltrials.Gov Identifier Nct01800487].

Twitter Demographics

The data shown below were collected from the profiles of 8 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 26 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 4%
United States 1 4%
Austria 1 4%
Unknown 23 88%

Demographic breakdown

Readers by professional status Count As %
Student > Doctoral Student 4 15%
Researcher 4 15%
Student > Master 4 15%
Student > Bachelor 3 12%
Librarian 2 8%
Other 9 35%
Readers by discipline Count As %
Medicine and Dentistry 13 50%
Unspecified 5 19%
Agricultural and Biological Sciences 3 12%
Pharmacology, Toxicology and Pharmaceutical Science 2 8%
Social Sciences 1 4%
Other 2 8%

Attention Score in Context

This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 June 2016.
All research outputs
#1,846,788
of 11,653,881 outputs
Outputs from BMC Complementary and Alternative Medicine
#450
of 2,415 outputs
Outputs of similar age
#48,392
of 243,126 outputs
Outputs of similar age from BMC Complementary and Alternative Medicine
#12
of 75 outputs
Altmetric has tracked 11,653,881 research outputs across all sources so far. Compared to these this one has done well and is in the 84th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,415 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.7. This one has done well, scoring higher than 81% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 243,126 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 80% of its contemporaries.
We're also able to compare this research output to 75 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 84% of its contemporaries.